These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34457331)

  • 1. A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase.
    Qiu S; Liu Y; Li Q
    R Soc Open Sci; 2021 Aug; 8(8):210066. PubMed ID: 34457331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
    Sharma A; Thelma BK
    J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural mechanism for Bruton's tyrosine kinase activation at the cell membrane.
    Wang Q; Pechersky Y; Sagawa S; Pan AC; Shaw DE
    Proc Natl Acad Sci U S A; 2019 May; 116(19):9390-9399. PubMed ID: 31019091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation mechanism and steady state kinetics of Bruton's tyrosine kinase.
    Dinh M; Grunberger D; Ho H; Tsing SY; Shaw D; Lee S; Barnett J; Hill RJ; Swinney DC; Bradshaw JM
    J Biol Chem; 2007 Mar; 282(12):8768-76. PubMed ID: 17264076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation loop phosphorylation modulates Bruton's tyrosine kinase (Btk) kinase domain activity.
    Lin L; Czerwinski R; Kelleher K; Siegel MM; Wu P; Kriz R; Aulabaugh A; Stahl M
    Biochemistry; 2009 Mar; 48(9):2021-32. PubMed ID: 19206206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Complementarity of Bruton's Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases.
    Najmi A; Thangavel N; Mohanan AT; Qadri M; Albratty M; Ashraf SE; Saleh SF; Nayeem M; Mohan S
    Pharmaceuticals (Basel); 2023 Mar; 16(3):. PubMed ID: 36986499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK.
    Kueffer LE; Joseph RE; Andreotti AH
    Front Cell Dev Biol; 2021; 9():655489. PubMed ID: 34249912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
    Liu J; Chen C; Wang D; Zhang J; Zhang T
    Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
    Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
    PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
    Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
    Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.
    Johnson AR; Kohli PB; Katewa A; Gogol E; Belmont LD; Choy R; Penuel E; Burton L; Eigenbrot C; Yu C; Ortwine DF; Bowman K; Franke Y; Tam C; Estevez A; Mortara K; Wu J; Li H; Lin M; Bergeron P; Crawford JJ; Young WB
    ACS Chem Biol; 2016 Oct; 11(10):2897-2907. PubMed ID: 27571029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatidylinositol 3-kinase-gamma activates Bruton's tyrosine kinase in concert with Src family kinases.
    Li Z; Wahl MI; Eguinoa A; Stephens LR; Hawkins PT; Witte ON
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13820-5. PubMed ID: 9391111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
    Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
    Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide].
    Mahajan S; Ghosh S; Sudbeck EA; Zheng Y; Downs S; Hupke M; Uckun FM
    J Biol Chem; 1999 Apr; 274(14):9587-99. PubMed ID: 10092645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QSAR analysis of nicotinamidic compounds and design of potential Bruton's tyrosine kinase (Btk) inhibitors.
    Santos-Garcia L; Assis LC; Silva DR; Ramalho TC; da Cunha EF
    J Biomol Struct Dyn; 2016 Jul; 34(7):1421-40. PubMed ID: 26305710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
    Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
    Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
    Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
    Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bruton's Tyrosine Kinase and Its Isoforms in Cancer.
    Wang X; Kokabee L; Kokabee M; Conklin DS
    Front Cell Dev Biol; 2021; 9():668996. PubMed ID: 34307353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.